Although numerous investigations have been brought forward, the reliable predictive biomarkers (including targets of sorafenib such as VEGF or MAPK/ERK) of sorafenib responses have not been ascertained so far in HCC patients. Here, VEGFA is linked to hepatocellular carcinoma.